MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2018 International Congress

    Inhibition of HDAC4 attenuates rotenone-induced abnormal increase of α-synuclein levels and affects autophagic flux in human dopaminergic SH-SY5Y cells

    L. Wang, L. Liu, T. Wang (Wuhan, China)

    Objective: To explore the effects of selective inhibition of HDAC4, on levels of α-syn and autophagy-related proteins in PD. To discuss the mechanism for the…
  • 2018 International Congress

    Directional Deep Brain Stimulation: First experiences in centers across the globe

    T. ten Brinke, V. Odekerken, J. Dijk, P. vd Munckhof, P. Schuurman, R. de Bie (Amsterdam-Zuidoost, Netherlands)

    Objective: To evaluate how clinicians are implementing directional DBS technology in their routine care. Background: Directional DBS is a new technology, which increases the clinician’s…
  • 2018 International Congress

    7 years later, are the Tomlinson’s levodopa dose equivalencies proposed consensual?

    E. Dellapina, F. Ory-Magne, A. Sommet, V. Rousseau, D. Devos, S. Thobois, L. Defebvre, C. Brefel-Courbon, JC. Corvol, O. Rascol, F. NS-PARK/FCRIN Network (Toulouse, France)

    Objective: (i) To collect all the levodopa equivalent doses (LED) formulae and references used in clinical trials in Parkinson’s disease (PD) since the publication of…
  • 2018 International Congress

    Design of a Pharmacokinetics Study with Multiple Doses of Accordion Pill™ Carbidopa/Levodopa in Patients with Parkinson’s disease

    C. Olanow, K. Kieburtz, J. Dubow, F. Stocchi, J. Meckler, N. Navon, R. Gendreau (Sarasota, FL, USA)

    Objective: To perform a pharmacokinetic (PK) study of the Accordion Pill™ carbidopa/levodopa (AP-CD/LD) and to determine if multiple doses can provide continuous delivery of LD.…
  • 2018 International Congress

    Relationship between Patient Global Impression of Change and other Efficacy Endpoints in Parkinson’s Disease: A post-hoc analysis from combined BIPARK-I and II

    J. Ferreira, W. Poewe, O. Rascol, R. Costa, E. Arbe, J-F. Rocha, P. Soares-da-Silva (Lisbon, Portugal)

    Objective: To evaluate the association of patients’ perception of Parkinson’s Disease (PD) symptoms improvement (as assessed by Patient Global Impression of Change, PGIC) could be…
  • 2018 International Congress

    The Interface of advanced therapies as Parkinson’s disease progresses – case reports

    C. Liang, S. Williams, L. Jones, C. Sue, P. Silberstein (St Leonards, Australia)

    Objective: To explore the practical benefits and challenges of adding duodenal levodopa-carbidopa intestinal gel infusion (LCIG) to subthalamic nucleus deep brain stimulation (STN DBS) in…
  • 2018 International Congress

    Treatment with levodopa/carbidopa intestinal gel of advanced Parkinson’s disease patients: Bulgarian experience

    E. Chorbadzhieva (Sofia, Bulgaria)

    Objective: To evaluate the efficacy of levodopa/carbidopa intestinal gel (LCIG) on motor fluctuations, dyskinesia, parkinson symptoms and quality of life in patients with late Parkinson’s…
  • 2018 International Congress

    Real-World Outcomes Using a Novel Directional Lead from a Deep Brain Stimulation (DBS) Registry for Parkinson’s Disease

    G. Deuschl, R. Jain, H. Scholtes, A. Wang, M. Barbe, A. Kühn, M. Pötter-Nerger, J. Volkmann, S. Paschen, J. Vesper (Kiel, Germany)

    Objective: The objective of this report is to assess the initial real-world outcomes using a directional lead with a Deep Brain Stimulation (DBS) system capable…
  • 2018 International Congress

    Study On Patient- And Caregiver-Reported Symptoms And Outcomes With Levodopa-Carbidopa Intestinal Gel For The Treatment Of Advanced Parkinson’s Disease. ADEQUA Study

    F. Valldeoriola, M.J. Catalán, F. Escamilla-Sevilla, E. Freire, J. Olivares, E. Cubo, D. Santos, J.C. Parra, G. Arroyo, J.M. Arbelo (Barcelona, Spain)

    Objective: The primary objective of the present study was to assess the effect of levodopa-carbidopa intestinal gel (LCIG) on the QoL of patients with advanced…
  • 2018 International Congress

    Effect of COMT-inhibitor in the clinical progression of Parkinson’s disease

    I.U. Song, K.S. Lee, Y.A. chung (Incheon, Republic of Korea)

    Objective: We conducted this 2-year follow-up study to evaluate whether or not catechol-O-methyltransferase inhibitor (COMTI) has an impact on the progression or severity of Parkinson's…
  • « Previous Page
  • 1
  • …
  • 1427
  • 1428
  • 1429
  • 1430
  • 1431
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley